GlassScriptPhysician profile
Brian T Miller
NPI 1790882108
$14,698.66
in general payments reported to CMS, 2019-2025
38 companies · $2,769 in 2025
The $2,769 reported for 2025 was more than what 78% of Allergy providers received nationally (typical 2025 total: $1,129).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,755 · 2020: $1,010 · 2021: $1,964 · 2022: $1,987 · 2023: $2,198 · 2024: $2,016 · 2025: $2,769.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,782 · Education: $201.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,782.35 |
| Education | $200.62 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $4,201.20 | 2019-2025 | Tezspire, Fasenra, Airsupra |
| Glaxosmithkline, LLC. | $2,947.42 | 2019-2025 | Trelegy Ellipta, Nucala, Arexvy |
| Genzyme Corporation | $989.80 | 2019-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $698.51 | 2020-2025 | Cuvitru, Glassia |
| Regeneron Healthcare Solutions, INC. | $683.46 | 2021-2025 | Dupixent |
| Mylan Specialty L.P. | $528.22 | 2019-2024 | Yupelri |
| Blueprint Medicines Corporation | $462.58 | 2022-2025 | Ayvakit |
| Grifols USA, LLC | $438.04 | 2019-2025 | Prolastin-C Liquid |
| Pfizer INC. | $408.12 | 2019-2025 | |
| Amgen INC. | $404.63 | 2022-2025 | Tezspire |
| Novartis Pharmaceuticals Corporation | $299.02 | 2019-2025 | |
| Genentech USA, INC. | $224.87 | 2019-2023 | Xolair |
| Ars Pharmaceuticals Operations, INC. | $213.74 | 2025 | Neffy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $191.28 | 2019-2022 | |
| Octapharma USA, INC. | $189.92 | 2021-2025 | Cutaquig, Panzyga |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $186.25 | 2021-2022 | |
| Teva Pharmaceuticals USA, INC. | $152.69 | 2019-2020 | |
| Alk-Abello, INC | $151.48 | 2019-2022 | |
| Biohaven Pharmaceuticals, INC. | $150.87 | 2021 | |
| Shire North American Group INC | $149.81 | 2019 | |
| Csl Behring | $142.89 | 2021-2025 | Hizentra |
| Depuy Synthes Sales INC. | $125.76 | 2019 | |
| Ionis Pharmaceuticals, INC. | $107.75 | 2025 | Dawnzera, Donidalorsen |
| Sanofi-Aventis U.S. LLC | $92.99 | 2019-2024 | |
| Kaleo, INC. | $86.04 | 2019-2023 | Auvi-Q |
| Hikma Pharmaceuticals USA | $69.41 | 2023-2025 | Ryaltris |
| Organon LLC | $65.14 | 2025 | Vtama |
| Sunovion Pharmaceuticals INC. | $62.24 | 2019 | |
| Verona Pharma, INC. | $54.16 | 2025 | Ohtuvayre |
| Optinose US, INC. | $49.75 | 2020-2023 | |
| Uswm, LLC | $38.00 | 2021 | |
| Eyevance Pharmaceuticals LLC | $30.77 | 2020-2021 | |
| Incyte Corporation | $27.88 | 2025 | Opzelura |
| Azurity Pharmaceuticals, INC. | $21.59 | 2025 | Alvesco |
| Viatris Specialty LLC | $20.15 | 2025 | Yupelri |
| Seqirus USA INC | $16.24 | 2024 | Flucelvax, Fluad |
| Merck Sharp & Dohme LLC | $15.99 | 2021 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brian Miller listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.